A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma
Esophagus · 2024
1 indexed replication failure in Immunology and Microbiology — real published studies, so you can learn what already failed before you repeat it.